Drug intelligence / Profile preview

tyrosinase peptide

Development stage: Phase 3
Modality: Peptides
Administration: Intramuscular, Subcutaneous, Intradermal, Topical, Oral

Overview

Tyrosinase peptide refers to recombinant peptides consisting of amino acid residues of the enzyme tyrosinase, a protein frequently expressed by melanoma cells. These peptides are primarily studied for their potential in cancer immunotherapy, particularly for melanoma treatment. Tyrosinase is a copper-containing enzyme that catalyzes the rate-limiting step in melanin production, making it an ideal target for both cancer vaccines and treatments for hyperpigmentation disorders.

Targets

TYR (Tyrosinase)

Beyond the preview

Go deeper on tyrosinase peptide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on tyrosinase peptide.

Explore the full profile